An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac®) in the treatment of recurrent respiratory tract infections in Thai patients

Asian Pacific Journal of Allergy and Immunology

Volumn 21, Issue 4, 2003, Pages 223-230

  Jareoncharsri, Perapun ^a   Bunnag, Chaweewan ^a   Tunsuriyawong, Prayuth ^a   Assanassane, Paraya ^a   Voraprayoon, Siriporn ^a   Pinkaew, Bangon ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LYSATE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUIVAC; LW 50020; PASPAT ORAL; STEROID;

ABSENTEEISM; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; LABORATORY TEST; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SCORING SYSTEM; TABLET FORMULATION; THAILAND;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RESPIRATORY TRACT INFECTIONS; THAILAND; TREATMENT OUTCOME;

EID: 2942588904     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Shapiro ED. Epidemiology of acute respiratory infections. Semin Pediatr Infect Dis 1998; 9: 31-6.
2. van Cauwenberge PV, Ingels K. Effect of viral and bacterial infection on nasal and sinus mucosa. Acta Otolaryngol (Stockh) 1996; 116: 316-21.
3. Barclay WS, Al-Nakib W, Higgin PG, Tyrrell DAJ. The time course of the humoral immune response to rhinovirus infection. Epidem Infect 1989; 103: 659-69.
4. Busse WW. The role of respiratory infections in airway hyperresponsiveness and asthma. Am J Respir Crit Care Med 1994; 150: 77-9.
5. Newman-Taylor A. Environmental determinants of asthma. Lancet 1995; 345: 296-9.
6. Cazzola M, Matera MG, Rossi F. Bronchial hyperresponsiveness and bacterial respiratory infection. Clin Ther 1991; 13: 157-71.
7. Clancy R, Pang G, Dunkley M, Taylor D, Cripps A. Acute or chronic bronchitis: a model of mucosal immunology. Immunol Cell Biol 1995; 73: 414-7.
8. Taylor DC, Clancy RL, Cripps AW, Butt H, Bartlett L, Murree-Allen K. An alteration in the host-parasite relationship in subjects with chronic bronchitis prone to recurrent episodes of acute bronchitis. Immunol Cell Biol 1994; 72: 143-51.
9. Paoletti P, Prediletto R, Carrozzi L, et al. Effects of childhood and adolescence-adulthood respiratory infections in a general population. Eur Respir J 1989; 2: 428-36.
10. Duijvestijn A, Hamann A. Mechanisms and regulation of lymphocyte migration. Immunol Today 1989; 10: 23-7.
11. Hapson LA, Brandtzaeg P. The mucosal defence system. In: Stiehem ER, ed., Immunological disorders infants and children, WB Saunders, Philadelphia, 1989; p. 116.
12. McGhee JR, Mestecky J, Dertzbaugh MT, Dldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10: 75-9.
13. Helmberg A, Bock G, Wolf H, Wick G. An orally administered bacterial immunomodulator primes rabbit neutrophils for increased oxidative burst in response to opsonized zymosan. Infect Immun 1989; 57: 3576-80.
14. Van Daal GJ, Beusenberg FD, So KL, et al. Protection against influenza virus infection in mice by oral immunization with a polyvalent bacterial lysate. Int J Immunopharmacol 1991; 13: 831-40.
15. Van Daal GJ, van't Veen A, So KL, et al. Oral immunization with polyvalent bacterial lysate and infection with Streptococcus pneumoniae: influence on interferon-gamma and PMN-elastase concentrations in murine bronchoalveolar lavage fluid. Int Arch Allergy Immunol 1992; 97: 173-7.
16. Ruedl CH, Albin B, Bock G, Wick G, Wolf H. Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer's patch lymphocyte traffic to the lung: possible implications for infectious disease prophylaxis and therapy. Int Immunol 1993; 5: 29-36.
17. Ruedl CH, Frühwirth M, Wick G, Wolf H. Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens. Clin Diagn Lab Immunol 1994; 1: 150-4.
18. Riedl-Seifert RJ, van Aubel A, Kämmereit A, Elsasser U. Recurrent infections during childhood - are they still a "crux medicorum"? Results of a placebo-controlled double-blind study with an oral bacterial lysate in children prone to infections. J Pharmacol Ther 1993; 3: 108-17.
19. Ruah SB, Abel S, Binder M, van Aubel A, Elsasser U, Kämmereit A. Paspat oral in Portugal-prevention and therapy of respiratory tract infections in infection-prone children. A double-blind, placebo-controlled, multicenter study, Study No. FK-09/92. Research Report. Munich, Germany, Luitpold Pharma, 1996.
20. Rutishauser M, Pitzke P, Grevers G, van Aubel A, Elsasser U, Kämmereit A. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study. Adv Ther 1998; 15: 330-41.
21. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145-60.
22. Grevers G, Palacios OA, Rodriguez B, Abel S. Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open, prospective, multinational study. Adv Ther 2000; 17: 103-16.